PDS Biotechnology Corp Interest Expense Nonoperating
PDS Biotechnology Corp (PDSB) reported Interest Expense Nonoperating of $3.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-13
- PDS Biotechnology Corp interest expense nonoperating for the quarter ending 2026-06-30 was $3.38M, a 57.58% increase year-over-year.
- PDS Biotechnology Corp interest expense nonoperating for the quarter ending 2026-03-31 was $1.01M, a 9.01% increase year-over-year.
- PDS Biotechnology Corp interest expense nonoperating for the quarter ending 2025-12-31 was $1.11M, a 1.56% increase year-over-year.
- PDS Biotechnology Corp interest expense nonoperating for the quarter ending 2025-09-30 was $1.15M, a 5.30% decline year-over-year.
- PDS Biotechnology Corp interest expense nonoperating for fiscal 2025 was $5.34M, a 14.24% increase from fiscal 2024.
- PDS Biotechnology Corp interest expense nonoperating for fiscal 2024 was $4.67M, a 11.11% increase from fiscal 2023.
- PDS Biotechnology Corp interest expense nonoperating for fiscal 2023 was $4.21M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.38M 10-Q · filed 2026-08-13 | $4.39M 10-Q · filed 2026-08-13 | $5.51M derived: sum of 3 quarters · filed 2026-08-13 | $6.66M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.01M 10-Q · filed 2026-05-14 | $2.13M derived: sum of 2 quarters · filed 2026-05-14 | $3.28M derived: sum of 3 quarters · filed 2026-05-14 | $5.42M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.26M derived: sum of 2 quarters · filed 2026-03-30 | $4.41M derived: sum of 3 quarters · filed 2026-08-13 | $5.34M 10-K · filed 2026-03-30 |
| 2025-09-30 | $1.15M 10-Q · filed 2025-11-13 | $3.29M derived: sum of 2 quarters · filed 2026-08-13 | $4.23M 10-Q · filed 2025-11-13 | $5.32M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $2.14M 10-Q · filed 2026-08-13 | $3.08M 10-Q · filed 2026-08-13 | $4.17M derived: sum of 3 quarters · filed 2026-08-13 | $5.39M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $930.88K 10-Q · filed 2026-05-14 | $2.03M derived: sum of 2 quarters · filed 2026-05-14 | $3.24M derived: sum of 3 quarters · filed 2026-05-14 | $4.43M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.31M derived: sum of 2 quarters · filed 2026-03-30 | $3.50M derived: sum of 3 quarters · filed 2026-03-30 | $4.67M 10-K · filed 2026-03-30 |
| 2024-09-30 | $1.21M 10-Q · filed 2025-11-13 | $2.40M derived: sum of 2 quarters · filed 2025-11-13 | $3.58M 10-Q · filed 2025-11-13 | $4.75M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.19M 10-Q · filed 2025-08-13 | $2.36M 10-Q · filed 2025-08-13 | $3.54M derived: sum of 3 quarters · filed 2025-08-13 | $4.61M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.17M 10-Q · filed 2025-05-14 | $2.35M derived: sum of 2 quarters · filed 2025-05-14 | $3.42M derived: sum of 3 quarters · filed 2025-05-14 | $4.41M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $2.24M derived: sum of 2 quarters · filed 2025-03-27 | $3.24M derived: sum of 3 quarters · filed 2025-03-27 | $4.21M 10-K · filed 2025-03-27 |
| 2023-09-30 | $1.07M 10-Q · filed 2024-11-14 | $2.06M derived: sum of 2 quarters · filed 2024-11-14 | $3.03M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $995.40K 10-Q · filed 2024-08-13 | $1.96M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |